Jill Feldman, MA

Jill Feldman is a lung cancer patient and advocate. When Jill was 13 years old, she lost her dad and two grandparents to lung cancer, and then her mom and close aunt died of lung cancer when she was in her 20’s. She became a volunteer, advocate, and past president of LUNGevity Foundation. In 2009, at 39 years old with four small children, Jill herself was diagnosed with EGFR positive lung cancer.

Jill is the incoming Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board. Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a planning committee member on IASLC’s North America Conference on Lung cancer, and a member of the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee. She is the patient advocate on the National Lung Cancer Round Table steering committee. Jill co-authored the ASTRO Guidelines for SBRT in early-stage lung cancer, published in an ASCO special article in the Journal of Clinical Oncology. Jill is committed to embedding a health equity lens in all her advocacy work.

In 2017, Jill co-founded the EGFR Resisters, a grassroots, patient-driven community committed to accelerating research that will prolong and better the lives of people diagnosed with EGFRm lung cancer. Jill continues to share her story to shine a light on lung cancer and end the stigma associated with it.

Disclosures:

• Employment: none
• Compensation: none
• Ownership: none
• Leadership: none